Clinical trials: Melanoma of Skin
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Advanced Melanoma
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
This is a phase 1b/2a study including a dose escalation part (Phase 1b) and an extension part (Phase 2a). Both parts will be open-label, multicenter study of OPM-101 combined with the anti-PD-1 pembrolizumab as per standard of…
- Trial name
- REVERT (NCT07040436)
- Testing
- OPM-101
- Volunteers
- 41 people
- Sponsor
- Oncodesign Precision Medicine
Breast Cancer, Non-small Cell Lung Cancer
BostonGene and Exigent Genomic INsight Study
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
- Trial name
- BEGIN (NCT06272864)
- Where
- 7 sites in United States
- Volunteers
- 400 people
- Sponsor
- BostonGene
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients…
- Trial name
- NCT07581509
- Testing
- Bmab1800, US-Licensed Keytruda
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Biocon Biologics UK PLC
Melanoma, Non Small Cell Lung Cancer
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- MSN (NCT02105168)
- Testing
- Blood sample, Tumorous biopsy, Healthy material sample
- Where
- France
- Volunteers
- 2,200 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cutaneous Malignant Melanoma
Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.
- Trial name
- NCT01482260
- Testing
- Biopsy
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Ruhr University of Bochum
Melanoma
Moletest Clinical Study in Scotland
To evaluate an iPad based photoimage analysis system (Moletest) for improving discrimination of benign from malignant suspicious skin lesions or moles.
- Trial name
- NCT02196246
- Where
- United Kingdom
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Moletest Scotland Ltd
Metastatic Melanoma, Skin Cancer
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Background: gp100 is a protein that is often found in melanoma tumors. An experimental procedure developed for treating patients with melanoma uses anti-gp100 cells designed to destroy their tumors.
- Trial name
- NCT00610311
- Testing
- cyclophosphamide, fludarabine phosphate, Aldesleukin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
- Trial name
- NCT04066725
- Testing
- Aspirin 81 mg, Aspirin 325mg
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- University of Utah
Melanoma (Skin)
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment.
- Trial name
- NCT00897520
- Testing
- recombinant interferon alfa, proteomic profiling, immunoenzyme technique
- Volunteers
- 40 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration.
- Trial name
- NCT06101134
- Testing
- relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab
- Where
- 31 sites in United States, Chile and 3 more
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.
- Trial name
- NCT06327698
- Testing
- Cadonilimab, anlotinib
- Volunteers
- 30 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Melanoma
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
The purpose of this study is to assess the safety and efficacy of combined treatment with Ipilimumab and all-trans retinoic acid (ATRA) in melanoma patients.
- Trial name
- NCT02403778
- Testing
- VESANOID, Ipilimumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Melanoma
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.
- Trial name
- NCT04979585
- Testing
- Camrelizumab, Anlotinib, nab-Paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Di Wu
Melanoma
Phase II, 2nd Line Melanoma - RAND Monotherapy
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137…
- Trial name
- NCT00612664
- Testing
- Anti-CD137 (4-1BB) (BMS-663513)
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 158 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
- Trial name
- NCT00289016
- Testing
- Talimogene Laherparepvec
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- BioVex Limited
Melanoma, Ovarian Cancer
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02015416
- Testing
- IDC-G305
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Metastatic Melanoma and Merkel Cell Carcinoma
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
This study will evaluate the preliminary safety, pharmacokinetics, and anti-tumor activity of pasireotide s.c. in patients with metastatic melanoma or metastatic Merkel cell carcinoma.
- Trial name
- NCT01652547
- Testing
- Pasireotide sub-cutaneous formulation, Pasireotide lon acting release formulation
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.